コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 k(cat)/K(m) against "poor" substrates (i.e., cefotaxime).
2 tants with greatly improved activity against cefotaxime.
3 Streptococcus pneumoniae to ceftriaxone and cefotaxime.
4 activity against the beta-lactam antibiotic cefotaxime.
5 e diarrhoea associated with increased use of cefotaxime.
6 and the majority of patients never received cefotaxime.
7 6A Toho-1 beta-lactamase with the antibiotic cefotaxime.
8 ch residues for the cephalosporin antibiotic cefotaxime.
9 populations correlate with activity against cefotaxime.
10 y in addition to amoxicillin, ampicillin and cefotaxime.
11 ling cephalosporins, such as Ceftriaxone and Cefotaxime.
12 confers resistance to ampicillin but not to cefotaxime.
13 in resistance to the beta-lactam antibiotic cefotaxime.
14 yzed by ESBLs in a manner similar to that of cefotaxime.
15 and the SHV-18-producing K. pneumoniae with cefotaxime.
16 rmediate and the transition to E' induced by cefotaxime.
17 te a transition state analog for turnover of cefotaxime.
18 25-2 microg/mL and reduced susceptibility to cefotaxime.
19 s with improved resistance to the antibiotic cefotaxime.
22 bited a minimum inhibitory concentration for cefotaxime 20,000-fold higher than wild-type TEM-1 and a
24 10,777 nonmeningeal isolates tested against cefotaxime, 79.2% were susceptible, 14.3% were intermedi
25 icrodilution method with ceftazidime (86) or cefotaxime (91) alone or in combination with clavulanate
26 ssing wild-type HipA were highly tolerant to cefotaxime, a cell wall synthesis inhibitor, to ofloxaci
27 onfirm our models' prediction that increased cefotaxime activity correlates with reduced Omega-loop f
29 ces the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MRSA infection.
31 entration neither Inh2-B1 nor Ceftriaxone or Cefotaxime alone was able to inhibit the growth of bacte
32 orized 111 of 138 isolates as susceptible to cefotaxime and 114 of 138 as susceptible to ceftriaxone.
33 etive category errors ranged from 12.2% with cefotaxime and 9.8% with ceftriaxone (due mainly to clus
34 ction reliably detect these isolates if both cefotaxime and ceftazidime are tested, but only about ha
35 croScan Neg MIC panel type 32) that included cefotaxime and ceftazidime tested alone or with a fixed
36 to third-generation cephalosporins, such as cefotaxime and ceftazidime, increasing hospital mortalit
41 m in diameter are predictably susceptible to cefotaxime and ceftriaxone, and those with smaller zones
44 alosporin with the gram-positive activity of cefotaxime and the gram-negative spectrum of ceftazidime
45 preterm infants demonstrates that meropenem, cefotaxime and ticarcillin-clavulanate are associated wi
46 mpicillin, and cefotaxime, Escherichia coli, cefotaxime, and cefepime, Pseudomonas aeruginosa, pipera
47 isolates of K. oxytoca, MICs of ceftazidime, cefotaxime, and ceftizoxime were elevated for strains pr
48 parenteral cephalosporins, such as cefepime, cefotaxime, and ceftriaxone, by 9.1 to 13.0%, bringing t
49 ommended interpretive criteria, ceftriaxone, cefotaxime, and ciprofloxacin had 100% categorical agree
51 isolates was resistant to tetracycline, SXT, cefotaxime, and extremely high levels of penicillin and
53 tive E. coli isolates that were resistant to cefotaxime, and sequence analysis confirmed that these p
54 early as high a risk of causing diarrhoea as cefotaxime, and the majority of patients never received
57 the other hand, however, the K(i) value for cefotaxime as an inhibitor of cephalothin hydrolysis is
58 with a general growth advantage, not only on cefotaxime but also on several other antibiotics that an
59 a K(i) value of 89 nM and reduced the MIC of cefotaxime by 64-fold in CTX-M-9 expressing Escherichia
60 Of the 21 isolates, 3 showed a CA effect for cefotaxime by BMD but not by disk diffusion testing.
61 were intermediate, and 22 were resistant to cefotaxime by MIC testing; 138 isolates were susceptible
62 is suggested that the first few turnovers of cefotaxime by the P99 beta-lactamase may be different fr
63 e, steady state parameters for hydrolysis of cefotaxime by this enzyme are as follows: k(cat) = 0.41
64 ses to 1 or more of ceftriaxone, cefuroxime, cefotaxime, cefepime, cefodizime, and ceftazidime; group
66 picillin-sulbactam, ticarcillin-clavulanate, cefotaxime, cefotetan, ceftriaxone, cefoxitin, and imipe
68 es were subjected to cefazolin, ceftriaxone, cefotaxime, ceftazidime, cefepime, and aztreonam agar di
69 cs containing an oxyimino group (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was
70 The isolates had low MICs to amoxicillin, cefotaxime, ceftriaxone, doxycycline, linezolid, meropen
71 nly" interpretive criteria were proposed for cefotaxime, ceftriaxone, meropenem, azithromycin, and mi
72 e isolates for which the MIC of ceftazidime, cefotaxime, ceftriaxone, or aztreonam was >or=2 microg/m
75 and was selected for increased resistance to cefotaxime, cefuroxime, ceftazadime, and aztreonam, i.e.
76 were susceptible to penicillin, amoxicillin, cefotaxime, cefuroxime, erythromycin, chloramphenicol, v
77 he improved activity against ceftazidime and cefotaxime, consistent with observations first made for
78 buted most to the loss rate of CFX, CFD, and cefotaxime (CTX) (t(1/2) = 4.5, 5.3, and 1.3 h, respecti
79 nhibitors able to potentiate the activity of cefotaxime (CTX) and ceftazidime (CAZ) against resistant
80 lenge isolates were tested against cefepime, cefotaxime (CTX), ceftriaxone (CTR), clindamycin (CLI),
81 tential ESBL producers (ceftazidime [CAZ] or cefotaxime [CTX] MICs were > or =2 microg/ml for all iso
82 sitive; i.e., the BMD MICs of ceftazidime or cefotaxime decreased by >/=3 doubling dilutions in the p
86 e, Streptococcus agalactiae, ampicillin, and cefotaxime, Escherichia coli, cefotaxime, and cefepime,
88 penicillin (from 21 percent to 25 percent), cefotaxime (from 10 percent to 15 percent), meropenem (f
92 ed included cefoxitin-piperacillin, imipenem-cefotaxime, imipenem-ceftazidime, imipenem-piperacillin-
93 n TEM-1 towards resistance on the antibiotic cefotaxime in an Escherichia coli strain with a high mis
94 ld increased activity against the antibiotic cefotaxime in enzyme assays, and the mutant enzymes all
98 Overall, the new M100-S12 ceftriaxone and cefotaxime interpretative breakpoints for nonmeningeal i
100 , cefepime (VM error, 6.2%; m error, 13.0%), cefotaxime (m error, 21.2%), ceftriaxone (m error, 23.3%
101 t in January 2002 introduced ceftriaxone and cefotaxime MIC interpretative breakpoints of < or =1 mic
103 alothin analogue lowered the ceftazidime and cefotaxime minimum inhibitory concentrations (MICs) of E
106 g in some medical centers, but 30-micrograms cefotaxime or 30-micrograms ceftriaxone disks are not re
109 e mutant proteins did not protect cells from cefotaxime or ofloxacin and had an impaired ability to p
112 cement of the deacylation rate was found for cefotaxime-PBP2x(R) complex (k(3) = 3 x 10(-4) s(-1)) as
116 Six of eight predicted mutations decrease cefotaxime resistance greater than 2-fold, while only on
118 As expected, one plasmid evolved increased cefotaxime resistance when appropriately strong cefotaxi
119 favor the divergence of one copy to improve cefotaxime resistance while maintaining the other copy t
126 ngitis due to penicillin-, ceftriaxone-, and cefotaxime-resistant Streptococcus pneumoniae is describ
128 tion model, and that taking antibiotics like cefotaxime should be thought of as a population rather t
129 oncentration (MIC) values to methicillin and cefotaxime showed increased rates of cell wall turnover
132 t of the initial enzyme form, E, which bound cefotaxime tightly, with a second more weakly binding fo
133 Analysis indicated that only two to three cefotaxime turnovers occurred during the K(i) determinat
135 e acyl enzyme adducts with cephaloridine and cefotaxime was confirmed by both electrospray and MALDI
137 hin, cefaclor, cefuroxime, cefoperazone, and cefotaxime) were isolated, and the MBL variants were cha
138 lysis of the third generation cephalosporin, cefotaxime, which is hydrolyzed by the cp228 enzyme 10-f
139 -lactam antibiotics such as penicillin-G and cefotaxime with normal, penicillin-susceptible PBP2x fro
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。